Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo
- PMID: 2023951
- PMCID: PMC51586
- DOI: 10.1073/pnas.88.9.4025
Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo
Abstract
Tumor necrosis factor (TNF) has pleiotropic effects on a wide variety of cell types. In vitro studies have demonstrated that TNF has antiviral properties and is induced in response to viral infections. However, a role for TNF in the antiviral immune response of the host has yet to be demonstrated. Here we describe the construction of and studies using a recombinant vaccinia virus that encodes the gene for murine TNF-alpha. By comparing the replication of and immune responses elicited by the TNF-encoding virus to a similarly constructed control virus, we hoped to observe immunobiological effects of TNF in the host. The in vivo experiments with this recombinant virus demonstrate that the localized production of TNF-alpha during a viral infection leads to the rapid and efficient clearance of the virus in normal mice and attenuates the otherwise lethal pathogenicity of the virus in immunodeficient animals. This attenuation occurs early in the infection (by postinfection hour 24) and is not due to the enhancement of cellular or antibody responses by the vaccinia virus-encoded TNF. This evidence suggests that attenuation of the recombinant virus is due to a direct antiviral effect of TNF on cells at the site of infection. Therefore, these results support the suggestion that TNF produced by immune cells may be an important effector mechanism of viral clearance in vivo.
Similar articles
-
The role for host-immune factors in the in vivo antiviral effects of tumour necrosis factor.Cytokine. 1995 Feb;7(2):157-64. doi: 10.1006/cyto.1995.1021. Cytokine. 1995. PMID: 7780035
-
The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model.J Virol. 1994 Jan;68(1):453-62. doi: 10.1128/JVI.68.1.453-462.1994. J Virol. 1994. PMID: 8254756 Free PMC article.
-
Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors.J Exp Med. 1997 Nov 3;186(9):1591-6. doi: 10.1084/jem.186.9.1591. J Exp Med. 1997. PMID: 9348317 Free PMC article.
-
Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice.Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10987-91. doi: 10.1073/pnas.91.23.10987. Proc Natl Acad Sci U S A. 1994. PMID: 7971996 Free PMC article.
-
TNF Decoy Receptors Encoded by Poxviruses.Pathogens. 2021 Aug 22;10(8):1065. doi: 10.3390/pathogens10081065. Pathogens. 2021. PMID: 34451529 Free PMC article. Review.
Cited by
-
Innate antiviral defenses in body fluids and tissues.Antiviral Res. 2000 Nov;48(2):71-89. doi: 10.1016/s0166-3542(00)00126-1. Antiviral Res. 2000. PMID: 11114410 Free PMC article. Review.
-
Chemokines cooperate with TNF to provide protective anti-viral immunity and to enhance inflammation.Nat Commun. 2018 May 3;9(1):1790. doi: 10.1038/s41467-018-04098-8. Nat Commun. 2018. PMID: 29724993 Free PMC article.
-
Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy.Immunol Lett. 2005 Aug 15;100(1):14-20. doi: 10.1016/j.imlet.2005.06.025. Immunol Lett. 2005. PMID: 16115692 Free PMC article. Review.
-
Gamma interferon controls mouse polyomavirus infection in vivo.J Virol. 2011 Oct;85(19):10126-34. doi: 10.1128/JVI.00761-11. Epub 2011 Jul 20. J Virol. 2011. PMID: 21775464 Free PMC article.
-
Initiation of primary anti-vaccinia virus immunity in vivo.Immunol Res. 2007;37(2):113-33. doi: 10.1007/BF02685894. Immunol Res. 2007. PMID: 17695247 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources